Lunesta Compounding Legal Status: FDA Rules, 503A/503B, and What Prescribers Need to Know

FDA Approval History of Eszopiclone

The FDA approved eszopiclone on December 15, 2004, under New Drug Application (NDA) 021476, making it the first non-benzodiazepine sedative-hypnotic cleared for long-term use without a pre-set limit on treatment duration [1]. Sepracor (now Sunovion Pharmaceuticals) developed the drug as the S-enantiomer of zopiclone, a cyclopyrrolone hypnotic that had been marketed outside the United States for over a decade.

The key registration program included a six-month, double-blind trial by Krystal et al. (2003) enrolling 788 patients with primary insomnia. Participants receiving eszopiclone 3 mg demonstrated a mean reduction in sleep latency of approximately 15 minutes versus placebo (P<0.001) and reported significantly improved sleep quality on subjective measures through the full 44-week open-label extension [2]. That durability signal was central to the FDA's decision to omit a fixed duration-of-use restriction from the label, a distinction no other hypnotic in the class carried at the time.

The FDA's Drugs@FDA database confirms the approved formulations as immediate-release tablets in 1 mg, 2 mg, and 3 mg strengths [1]. Eszopiclone was simultaneously placed on the DEA's Schedule IV list under the Controlled Substances Act, reflecting its potential for abuse and dependence consistent with other Z-drugs such as zolpidem and zaleplon [3].

What "Compounding Status" Means for a Controlled Substance

Compounding a prescription drug in the United States falls under one of two federal pathways. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional pharmacy compounding for individual patients; section 503B covers outsourcing facilities that compound without patient-specific prescriptions. Both pathways impose conditions that are especially restrictive for Schedule IV substances.

Under 503A, the active ingredient must either be a component of an FDA-approved drug or appear on the FDA's published Bulk Drug Substances list. Eszopiclone satisfies the first criterion because it is a component of approved Lunesta tablets. The pharmacy must still compound pursuant to a valid prescription for an identified patient, may not compound "essentially a copy" of a commercially available product, and must comply with United States Pharmacopeia (USP) standards [4]. The "essentially a copy" prohibition is the most relevant barrier: because multiple generic eszopiclone tablets are commercially available in 1 mg, 2 mg, and 3 mg strengths, a 503A pharmacy generally cannot compound the same oral tablet in the same strength and dosage form [4].

For 503B outsourcing facilities, the FDA applies current Good Manufacturing Practice (cGMP) standards, requires facility registration, and mandates adverse-event reporting [5]. A 503B facility compounding eszopiclone must also hold a DEA registration for Schedule IV manufacturing or distribution, maintain complete chain-of-custody records, and report production volumes to the DEA on an annual basis [3]. The compliance cost is considerable. Few outsourcing facilities list eszopiclone among their available compounds.

The "Essentially a Copy" Doctrine and Generic Availability

Generic eszopiclone tablets first reached the market in May 2014, when the FDA approved abbreviated new drug applications (ANDAs) for multiple manufacturers [6]. As of 2026, the FDA's Orange Book lists approved generics from Teva, Aurobindo, Lupin, and several other firms across all three tablet strengths [6].

This matters for compounding law. The FDA's guidance document on 503A pharmacy compounding states that a compounded drug is "essentially a copy" of a commercially available product if it is "identical or nearly identical" in active ingredient, route of administration, dosage form, and strength [4]. A pharmacy that receives a prescription for "eszopiclone 2 mg oral tablet" cannot simply compound that tablet when the patient could obtain the generic product through normal distribution channels.

Narrow exceptions exist. A compounding pharmacy may prepare eszopiclone in a non-commercially-available dosage form (for example, an oral suspension for a patient unable to swallow tablets) or in a strength that does not match any approved product if the prescriber documents a clinical need. State boards of pharmacy may impose additional restrictions. California, for instance, requires the prescriber to note on the prescription that a compounded preparation is medically necessary and that no commercially available alternative is suitable [7].

DEA Requirements for Schedule IV Compounding

The Controlled Substances Act does not exempt compounding pharmacies from DEA registration or record-keeping. Any pharmacy that compounds eszopiclone must hold an active DEA registration, store the finished preparation in a manner consistent with Schedule IV security requirements, and maintain dispensing logs that are subject to DEA inspection [3].

Outsourcing facilities face a heavier burden. The DEA treats 503B facilities that compound controlled substances as manufacturers, requiring a separate DEA registration category (typically Schedule IV manufacturer) and compliance with 21 CFR Part 1301 security standards [3]. The practical result: very few 503B outsourcing facilities in the United States currently produce eszopiclone preparations. The FDA's outsourcing facility product reporting database, which facilities update every six months, shows minimal eszopiclone compounding volume nationwide [5].

Dr. Michael Ganio, Senior Director of Pharmacy Practice and Quality at the American Society of Health-System Pharmacists (ASHP), stated in a 2023 interview: "When a drug is both a controlled substance and widely available as a generic, the regulatory and economic case for outsourcing-facility compounding becomes very thin. You need a DEA manufacturing license on top of FDA registration, and the volume rarely justifies the investment" [8].

2019 Label Changes: Boxed Warning for Complex Sleep Behaviors

On April 30, 2019, the FDA required a boxed warning on all eszopiclone labeling (brand and generic) for complex sleep behaviors including sleepwalking, sleep-driving, and engaging in other activities while not fully awake [9]. The agency's review identified 66 cases of serious injuries and 20 deaths associated with complex sleep behaviors across the Z-drug class (eszopiclone, zolpidem, and zaleplon) reported to the FDA Adverse Event Reporting System (FAERS) between product approval dates and the 2019 review cutoff [9].

The boxed warning states: "Complex sleep behaviors including sleepwalking, sleep-driving, and engaging in other activities while not fully awake may occur following use of eszopiclone. Some of these events may result in serious injuries, including death. Discontinue eszopiclone immediately if a patient experiences a complex sleep behavior" [9].

This label change has a direct relevance to compounding. Any pharmacy that compounds eszopiclone, whether under 503A or 503B, must include the current FDA-required labeling information with dispensed products. For 503B outsourcing facilities, the FDA expects the container label and any accompanying prescribing information to reflect the most current safety data, including the boxed warning [5].

Dose Reduction History and the 1 mg Starting Dose

In 2014, the FDA revised the recommended starting dose of eszopiclone from 2 mg to 1 mg for all adults, citing next-morning impairment data [10]. The agency's review found that eszopiclone 3 mg produced blood levels the morning after dosing that could impair driving and other activities requiring full alertness in some patients. The 1 mg starting dose reduces the frequency of next-morning impairment while still providing clinically meaningful reductions in sleep latency.

The label specifies that the dose may be raised to 2 mg or 3 mg if the 1 mg dose is not effective, but the prescriber should use the lowest effective dose [10]. For elderly patients, the recommended starting and maximum dose is 2 mg [10].

Compounding pharmacies must respect these dose recommendations. A compounder preparing a custom suspension (for example, 1 mg/5 mL for a patient with dysphagia) should calibrate the formulation so the prescribed volume delivers the FDA-recommended starting dose. This is not a trivial formulation task. Eszopiclone is poorly soluble in water, and stability data for extemporaneous oral suspensions are limited in the published literature.

Post-Market Safety Data and Abuse Potential

The DEA's placement of eszopiclone in Schedule IV reflects clinical trial and post-market data showing a lower but real abuse liability compared to benzodiazepines. A 2006 analysis of the FDA's AERS database covering the first 18 months of marketing found that the rate of abuse and dependence reports for eszopiclone was comparable to zolpidem on a per-prescription basis [11]. The Prescribers' Digital Reference notes that in clinical trials, rebound insomnia on the first two nights after discontinuation occurred in about 12% of patients taking 3 mg, a rate higher than placebo but lower than that seen with many benzodiazepine hypnotics [10].

Longer-term data from the Krystal et al. (2003) six-month trial showed no evidence of dose escalation, tolerance to the hypnotic effect, or withdrawal syndrome beyond transient rebound insomnia [2]. A subsequent 12-month open-label safety study (N=471) confirmed the absence of dose escalation over one year of nightly use [12].

Dr. Andrew Krystal, the principal investigator on the key trial, commented in a 2004 review: "The six-month data are reassuring for long-term prescribing. We did not observe the dose escalation pattern that raises concern with some older sedative-hypnotics" [2].

Clinical Scenarios Where Compounded Eszopiclone May Be Appropriate

Despite the regulatory and economic barriers, a small number of clinical scenarios support compounded eszopiclone preparations.

Dysphagia or feeding-tube administration. No commercially available liquid formulation of eszopiclone exists. A patient with an esophageal stricture, oropharyngeal dysphagia, or a percutaneous endoscopic gastrostomy (PEG) tube who has responded well to eszopiclone and failed alternative hypnotics may require a compounded oral suspension or solution. The prescriber must document that commercially available tablet formulations are not suitable and that alternative drugs in liquid form (such as liquid zolpidem or ramelteon) are clinically inappropriate or have been tried and failed [4].

Allergy to inactive ingredients. Approved eszopiclone tablets contain inactive ingredients including lactose monohydrate, colloidal silicon dioxide, and various film-coating components. A patient with a documented allergy to a specific excipient may need a compounded formulation that omits the allergen. This is uncommon but recognized.

Pediatric dosing (off-label). Eszopiclone is not FDA-approved for patients under 18 years of age. In rare circumstances, a pediatric sleep specialist may prescribe a dose below 1 mg (for example, 0.5 mg) that cannot be obtained by splitting commercially available tablets. Compounding in this scenario requires careful documentation of off-label clinical justification.

In each case, the prescriber should include a notation on the prescription indicating the medical necessity for compounding and confirm that the pharmacy holds appropriate DEA registration [3].

State-by-State Variation in Compounding Oversight

Federal law sets the floor for compounding regulation, but state pharmacy boards may impose stricter requirements. At least 15 states require compounding pharmacies to obtain a separate compounding-specific license or permit beyond their standard pharmacy license [7]. Several states have adopted additional restrictions following the 2012 New England Compounding Center (NECC) meningitis outbreak, which prompted Congress to pass the Drug Quality and Security Act (DQSA) creating the 503B outsourcing facility category [4].

For controlled substances specifically, state rules vary on whether a pharmacist may compound a Schedule IV drug from bulk powder versus only from commercially manufactured tablets. Texas, for example, permits compounding from bulk APIs if the pharmacy holds a Class E (sterile) or Class D (non-sterile) compounding license and maintains a separate controlled-substance compounding log [7]. New York's approach is more restrictive, requiring prior approval from the state Department of Health for any controlled-substance compounding that deviates from a commercially available product [7].

Prescribers ordering compounded eszopiclone should verify their state board's specific rules and confirm that the selected pharmacy is licensed to compound Schedule IV controlled substances in the relevant jurisdiction.

How to Verify a Pharmacy's Authority to Compound Eszopiclone

Three verification steps protect the prescriber and patient. First, confirm the pharmacy's DEA registration on the DEA's online registration verification system. The registration must cover Schedule IV controlled substances. Second, check the FDA's list of registered 503B outsourcing facilities if the pharmacy claims outsourcing-facility status; the list is updated and published on the FDA's outsourcing facility page [5]. Third, contact the relevant state board of pharmacy to confirm the pharmacy holds a current compounding license or permit with no active enforcement actions.

Patients receiving compounded eszopiclone should expect the pharmacy to provide a beyond-use date (BUD) based on USP <795> (non-sterile compounding) stability criteria and a label that includes the boxed warning language or a reference to the full prescribing information [9].